Date: 2017-08-29
Type of information: Distribution agreement
Compound: Iluvien® (fluocinolone acetonide intravitreal implant)
Company: Alimera Sciences (USA - GA) Horus Pharma (France)
Therapeutic area: Ophtalmological diseases
Type agreement: distribution
Action mechanism:
- corticosteroid. Iluvien® (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant that releases sub-microgram levels of fluocinolone acetonide for up to 36 months for the treatment of chronic diabetic macular edema . The implant provides a therapeutic effect of up to 36 months by delivering sustained sub-microgram levels of fluocinolone acetonide. Iluvien® is injected in the back of the patient's eye to a position that takes advantage of the eye's natural fluid dynamics. The applicator employs a 25-gauge needle, which allows for a self-sealing wound.
Disease: diabetic macular edema
Details:
- • On August 29, 2017, Alimera Sciences announced that its European subsidiary based in the United Kingdom, has signed a distribution agreement with Horus Pharma . Under the agreement, Horus will serve as Alimera’s exclusive distributor in France for Iluvien®, Alimera's sustained release intravitreal injection for the treatment of diabetic macular edema.
Horus will negotiate with the Comité Economique des Produits de Santé, the Union Nationale des Caisses d’Assurance Maladie, the French National Authority for Health and other French regulatory authorities regarding the appropriate public price and confidential net price for reimbursement for Iluvien®. In addition, Horus will handle promotion, marketing and commercial activities in France for Iluvien®.
Financial terms:
Latest news:
Is general: Yes
